Liver study aims to make cancer drug safer for patients with liver disease
NCT ID NCT07102095
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how moderate liver problems change the way the body handles sevabertinib, an experimental cancer drug for tumors with HER2 mutations. About 20 people—10 with liver impairment and 10 healthy volunteers—will take a single dose and have their blood levels measured. The goal is to see if liver disease affects drug exposure, so doctors can adjust doses for cancer patients with liver issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sevabertinib (BAY 2927088)
What this could lead to
If successful, this study could help doctors decide the right dose of sevabertinib for cancer patients with liver problems, making the drug safer and more effective for them.
What could go wrong
This is a very early, small study with only 20 people, so results may not apply to all patients. The drug is still experimental, and liver impairment might change drug levels in unpredictable ways.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami - Oncology
Miami, Florida, 33014, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States